Project description:

MVI is taking steps to address the possibility that the leading TBV antigens may be poorly immunogenic when delivered as soluble recombinant proteins with adjuvant in humans. Significant challenges have been encountered in producing sexual sporogonic mosquito (SSM) antigens that adopt native conformations in recombinant systems due to multiple cysteine residues and complex tertiary structures. MVI is therefore evaluating alternative delivery approaches with the aim of enhancing induction of functional transmission-blocking antibodies. In parallel, we are supporting the development of a panel of biochemical assays to better characterize each of the lead antigens as they become available and complement the small animal immunogenicity assessments.